Irhythm (IRTC) Stock
Wearable heart rhythm monitoring with cloud analytics. Here's the price, business snapshot, and what's worth knowing about Irhythm in October 2026.
iRhythm Technologies (IRTC) develops and operates the Zio ambulatory electrocardiogram (ECG) service: a wearable patch and cloud-based analytics that detect cardiac arrhythmias. Investors should know the business mixes device sales with recurring diagnostic and analytics revenue, giving exposure to both one-off volume and higher-margin service economics. Growth has been driven by broader use of remote cardiac monitoring, partnerships with providers, and improved AI-driven interpretation. Key risks include reimbursement pressure, regulatory scrutiny, competition from other wearables and implantable monitors, and dependence on physician adoption. Profitability has varied as the company invested in scaling operations and product development. For longer-term investors, the case rests on continued clinical adoption, stable reimbursement, and execution on margin expansion. This summary is general educational information, not personalised investment advice; values can rise and fall and past performance is not a reliable guide.
Irhythm (IRTC) Stock Forecast
Analyst price target, next 12 months
$148.17
+34.2% vs today's $110.37
Price range over the last 12 months
Close to its 12-month low
Analysts covering Irhythm have a consensus 12-month target of $148.17, above the current price of $110.37.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Irhythm Holdings' stock, expecting significant price growth ahead.
Financial Health
iRhythm Holdings is performing well with strong revenue and cash flow, indicating healthy financial management.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Wearable ECG Leader
Zio’s patch and analytics create a recognised monitoring service; recurring diagnostic revenue is a notable feature, though future returns depend on continued adoption and reimbursement.
Clinical Adoption Trends
Remote monitoring and guideline support could expand use across healthcare systems, yet slower uptake or reimbursement shifts would weigh on revenue.
Competition & Tech
AI-driven interpretation and product improvements are advantages, but competition from wearables and implantables presents execution and margin risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
